Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, are multipotent cells capable of differentiating into various cell types, including osteoblasts (bone), chondrocytes (cartilage), adipocytes (fat), and, to a lesser extent, muscle, neural, endothelial, and hepatocyte lineages[1][2][8]. They are found in multiple tissues, including bone marrow, adipose tissue, and umbilical cord. The promotion of MSC differentiation refers to stimulating these cells to adopt specific fates, often by modulating key signaling pathways such as Wnt, TGF-β, FGF, and Hedgehog[5][6][9]. This process is central to the fields of regenerative medicine and cell therapy, where directed differentiation of MSCs is harnessed for tissue repair, but it is not itself a single druggable target or protein receptor—rather, it is a biological outcome of multiple pathway interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mesenchymal stem cell (or Mesenchymal stromal cell) (MSC).